Engineered Probiotics

Pioneering the third generation of probiotics

Probiotics engineered for specific medical conditions — designed with precision, validated by science.

Scroll

Our Mission

Engineering safe and affordable probiotics for medical conditions

First-generation probiotics were derived from food, supporting general gut health. The bioinformatics revolution gave rise to second-generation probiotics — strains linked to health benefits. However, their effects were largely associative, with limited testing in humans and unclear impact on specific diseases.

Today, Concordance is pioneering third-generation probiotics — engineered for precise, mechanism-driven effects with efficacy validated in human clinical studies.

236M+

Antibiotic prescriptions written annually in the U.S.

700

Prescriptions per 1,000 people each year

3rd Gen

Engineered for precision, validated in clinical studies

The Challenge

NSAIDs and gastrointestinal toxicity

Our gastrointestinal tract is lined by a complex barrier that protects the body. This barrier relies on healthy epithelial cells, mucus production, and a balanced gut microbiome.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications worldwide. While effective for pain and inflammation, they disrupt gut integrity by inhibiting prostaglandin synthesis, weakening mucosal defenses, increasing intestinal permeability, and altering the gut microbiome.

NSAIDs are essential medicines, but their widespread use raises a critical question: how can we protect the gut while preserving their benefits?

Our Product

About CTX-101

CTX-101 is an engineered probiotic designed for use alongside NSAIDs. It is being developed as a medical food for the dietary management of NSAID-associated disruption to gut integrity and function.

Food-grade probiotic with a history of safe use in humans

Already manufactured commercially in a cost-efficient and scalable way

Mechanism-driven — engineered for precise effects on gut integrity

Our People

Meet the team

Justin Hayes

Chief Executive Officer

Justin is CEO of Concordance. He is a metabolic engineer and entrepreneur. During his time at Northeastern University, Justin developed the core technology and business strategy for Concordance. He received his Ph.D. in chemical engineering and founded and led the company since 2024.

LinkedIn →

Pioneering the third generation of probiotics

Engineering safe and affordable probiotics for medical conditions

236M+

700

3rd Gen

NSAIDs and gastrointestinal toxicity

About CTX-101

Meet the team

Justin Hayes

Updates

Concordance Wins Silicon Valley Bank-Babson Pitch Competition

Concordance Moves into The Engine

CEO Justin Hayes Presents at Microbiome Times Summit in Brussels

Let's start a conversation